摘要:
The invention concerns heterocyclic compounds of the general formula (I) in which A, B, R, R.sup.2, R.sup.3, W, Y, Z.sup.1, Z.sup.2 and r are as defined in the description, methods of preparing them and their use as inhibitors of thrombocyte aggregation, the metastization of carcinoma cells and the binding of osteoclasts on bone surfaces. ##STR1##
摘要:
5-Membered ring heterocycle of the formula I, in which D includes a COOR15, CON(CH3)R15 or CONHR15 radical and R15 includes a 6-24 member bicyclic or tricyclic radical, compositions, preparation and use as inhibitors of thrombocyte aggregation, metastasization of carcinoma cells, binding of osteoclasts to bone surfaces and for the treatment of tromboses.
摘要:
The present invention pertains to 5-ring heterocycles of general formula (I), wherein W, Y, Z, B, D, E and R as well as b, c, d, e, f, g, and h are as indicated in the description; to methods for preparing them, and to their use as inhibitors of platelet aggregation, metastasizing of carcinomatous cells and the attachment of osteoclasts to the bone surface. ##STR1##
摘要:
Urea derivates are disclosed having the formula (I). ##STR1## in which A, B, W, Z, R, R.sup.1, R.sup.2, R.sup.3 and r have the meaning given in the description, as well as a process for preparing the same and their use as inhibitors of thrombocyte aggregation, carcinom cell metastasis and osteoclast binding to bone surface.
摘要:
The present invention relates to novel substituted amino compounds of the formula I: R.sup.1 -(A).sub.a -(B).sub.b -(D).sub.c -(CH.sub.2).sub.m -N(R.sup.2)-(CH.sub.2).sub.n -R.sup.3 as defined in the present application, and to a process for preparing such compounds. The invention also includes pharmaceutical compositions containing the present compounds, and the preparation of such compositions. The invention also relates to the use of the present compounds as inhibitors of blood-platelet aggregation, formation of metastases by carcinoma cells, and the binding of osteoclasts to bone surfaces, in the treatment of hosts in need thereof.
摘要:
Phenylimidazolidine derivatives of the general formula I ##STR1## in which, for example, Y denotes --CH.sub.2 --CH.sub.2 --CO--r denotes 0 to 3Z denotes oxygenW denotes hydroxylR.sup.1 denotes --NH--C(.dbd.NH)--NH.sub.2R, R.sup.2, R.sup.3 denote hydrogenR.sup.4 denotes --CO--NHR.sup.5,where --NH--R.sup.5 represents an .alpha.-amino acid radical, have useful pharmacological properties such as inhibition of platelet aggregation and osteoclast binding to the bone surfaces.
摘要:
The present invention relates to compounds of the general formula I ##STR1## in which R, R.sup.1 to R.sup.4, r, Y, Z and W are defined as indicated in the description, a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
摘要:
Aspartic acid derivatives of the formula ##STR1## in which X denotes, for example, ##STR2## and R denotes, for example, cyclohexylamino, have useful pharmacological properties.
摘要:
The present invention relates to hydantoin derivatives of the formula I ##STR1## and which are intermediates for the preparation of pharmaceutical active compounds, their preparation and their use in the preparation of the active compounds.
摘要:
The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.